Medical Science Liaison (Washington D.C. and Philadelphia ) # 4801

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.\n\n

We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.\n\n

GRAIL is headquartered in the bay area of California, with locations in Washington, D.

C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.\n\n

For more information, please visit grail.com\n\n

The primary responsibility of the Medical Science Liaison (MSL) supporting Galleri is to engage, educate, and support Galleri ordering providers and cancer diagnostic specialists, oncologists, Key Opinion Leaders (KOLs), and Health Care System (HCS) influencers with the most current clinical and scientific materials supporting appropriate implementation and utilization of the Galleri Multi-Cancer Early Detection (MCED) test. This will be completed through (1) Medical-Commercial partnership to identify appropriate external stakeholders, (2) providing necessary and appropriate medical education with slides, abstracts, and/or publications relevant to the Galleri product and related services, (3) responding to unsolicited questions, (4) participating in the development and creation of educational resources, and (5) training external speakers.